Oramed Pharmaceuticals (ORMP) Research & Development (2011 - 2026)

Oramed Pharmaceuticals has reported Research & Development for 15 years, with the latest figure at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 27.74% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $5.8 million (down 21.52% YoY), and the FY2025 full-year result was $6.4 million, up 0.9% from the prior year.
• Research & Development for Q1 2026 stood at $1.6 million, down from $2.0 million in the prior quarter.
• The five-year high for Research & Development was $9.2 million in Q2 2022, with the low at $957000.0 in Q3 2023.
• Historically, Research & Development has averaged $3.1 million across 5 years, with a median of $1.8 million in 2023.
• Annual changes were most pronounced in 2023 — Research & Development tumbled 82.1% — and 2024, when it jumped 134.27%.
• Oramed Pharmaceuticals' Research & Development stood at $9.0 million in 2022, then plunged by 80.46% to $1.8 million in 2023, then decreased by 17.27% to $1.5 million in 2024, then surged by 36.07% to $2.0 million in 2025, then dropped by 19.82% to $1.6 million in 2026.
• The last three Research & Development figures came in at $1.6 million (Q1 2026), $2.0 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.